Pegozafermin Is a Potential Master Therapeutic Regulator in Metabolic Disorders: A Review

PEGOZAFERMIN PROVIDES BENEFICIAL LIPID EFFECTS IN SUBJECTS WITH SEVERE HYPERTRIGLYCERIDEMIA REGARDLESS OF BACKGROUND LIPID MODIFYING THERAPY STATUS: AN ANALYSIS OF THE PHASE 2 ENTRIGUE STUDY

(2023) Deepak L. Bhatt et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial

(2023) Deepak L. Bhatt et al.   NATURE MEDICINE

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH

(2023) Rohit Loomba et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pegozafermin for the treatment of non-alcoholic steatohepatitis patients with F2/F3 fibrosis: a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial (ENLIVEN)

(2023) Rohit Loomba et al.   JOURNAL OF HEPATOLOGY

The Novel GlycoPEGylated FGF21 Analog Pegozafermin Activates Human FGF Receptors and Improves Metabolic and Liver Outcomes in Diabetic Monkeys and Healthy Human Volunteers

(2023) Moti Rosenstock et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Pegozafermin led to significant metabolic benefits, in addition to robust beneficial effects on the liver, in an open-label cohort of a Phase 1b/2a study in subjects with non-alcoholic steatohepatitis (NASH)

(2022) Naim Alkhouri et al.   JOURNAL OF HEPATOLOGY

Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study

(2022) Rohit Loomba et al.   Lancet Gastroenterology & Hepatology

Another arrow in the NASH quiver?

(2022) Roberta Forlano et al.   Lancet Gastroenterology & Hepatology

Global Incidence and Prevalence of Non-alcoholic Fatty Liver Disease

(2022) Margaret LP Teng et al.   Clinical and Molecular Hepatology

The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic

(2020) Leiluo Geng et al.   Nature Reviews Endocrinology

Baseline HOMA IR and Circulating FGF21 Levels Predict NAFLD Improvement in Patients Undergoing a Low Carbohydrate Dietary Intervention for Weight Loss: A Prospective Observational Pilot Study

(2020) Mikiko Watanabe et al.   Nutrients

BIO89-100, a GlycoPEGylated FGF21 Analog, Improved Serum Lipids and Extended Half-Life in a Controlled Single Ascending Dose Trial in Healthy Subjects†

(2020) Maya Margalit et al.   Journal of Clinical Lipidology

EDP-297, a novel and potent fxr agonist, exhibit robust anti-fibrotic effects with significant liver function in a rat model of non-alcoholic steatohepatitis

(2020) Mozhdeh Sojoodi et al.   JOURNAL OF HEPATOLOGY

Diagnosis of non-alcoholic fatty liver disease (NAFLD): current concepts.

(2019) Margarita Papatheodoridi et al.   CURRENT PHARMACEUTICAL DESIGN

Plasma Fibroblast Growth Factor 21 is Associated with Severity of Nonalcoholic Steatohepatitis in Patients with Obesity and Type 2 Diabetes

(2019) Diana Barb et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

FGF21 activation-mediated islet autophagy in Type 2 diabetes with pharmacotherapeutic potential

(2019) Po Sing Leung   Future Medicinal Chemistry

Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity

(2019) Zachary J. Ward et al.   NEW ENGLAND JOURNAL OF MEDICINE

Role of adipokines FGF21, leptin and adiponectin in self-concept of youths with obesity

(2018) Ge Li et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis

(2018) Zobair M. Younossi et al.   HEPATOLOGY

Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction

(2017) et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance

(2017) Ruth C. R. Meex et al.   Nature Reviews Endocrinology

Understanding the Physiology of FGF21

(2016) Ffolliott Martin Fisher et al.   Annual Review of Physiology

FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues

(2016) Christian Schlein et al.   Cell Metabolism

Fibroblast growth factor-21, energy balance and obesity

(2015) Marta Giralt et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY